0001193125-16-732168.txt : 20161006 0001193125-16-732168.hdr.sgml : 20161006 20161006091532 ACCESSION NUMBER: 0001193125-16-732168 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20161003 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20161006 DATE AS OF CHANGE: 20161006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 161923987 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d256876d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2016

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction

of incorporation or organization)

 

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 3, 2016, Amedisys, Inc. (the “Company”) and Martin B. Howard, the Company’s Chief Information Officer, mutually agreed that Mr. Howard will be leaving the Company effective as of October 31, 2016. Mr. Howard’s departure from the Company will constitute a termination without cause. Michael North, the Company’s Senior Vice President of Operations, who was responsible for the Company’s conversion to Homecare Homebase (a leading platform for home health and hospice companies), will serve as the Company’s Interim Chief Information Officer.

 

Item 7.01. Regulation FD Disclosure.

On October 6, 2016, the Company issued a press release announcing that Mr. Howard is leaving the Company, effective October 31, 2016, and that Mr. North will assume the role of Interim Chief Information Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated October 6, 2016


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:  

/s/ Paul B. Kusserow

Paul B. Kusserow
President and Chief Executive Officer
DATE: October 6, 2016


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press Release dated October 6, 2016
EX-99.1 2 d256876dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   

Media Contact:

Kendra Kimmons

Marketing & Communications

225-299-3720

kendra.kimmons@amedisys.com

Chief Information Officer Leaving Amedisys

BATON ROUGE, La., October 6, 2016 – Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health and hospice companies, announced today that Martin B. Howard, Chief Information Officer, is leaving Amedisys, effective October 31, 2016.

“We are grateful to Marty for his contributions to Amedisys, and thank him for lending his considerable talents,” stated Amedisys President and Chief Executive Officer Paul Kusserow. “His commitment to excellence and knowledge of health information technology has helped Amedisys optimize the IT elements of our transformative strategy.”

Michael North, Senior Vice President of Operations, will assume the role of interim Chief Information Officer. North, a seasoned IT executive, most recently led Amedisys’ successful conversion to the Homecare Homebase platform. Before Amedisys, he served as the Director of Corporate Development Integrations for Humana. His senior level responsibilities included all IT and operational integrations for acquisitions. Prior to that, North served as the Director of IT Support with Kindred Healthcare.

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

GRAPHIC 3 g256876g1006044033386.jpg GRAPHIC begin 644 g256876g1006044033386.jpg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end GRAPHIC 4 g256876g1006044214272.jpg GRAPHIC begin 644 g256876g1006044214272.jpg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end